Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection in the Netherlands, September to December 2022
View ORCID ProfileAnne J. Huiberts, View ORCID ProfileBrechje de Gier, Christina E. Hoeve, Hester E. de Melker, Susan J.M. Hahné, View ORCID ProfileGerco den Hartog, View ORCID ProfileJanneke H.H.M. van de Wijgert, Susan van den Hof, Mirjam J. Knol
doi: https://doi.org/10.1101/2023.02.08.23285643
Anne J. Huiberts
1Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands
Brechje de Gier
1Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands
Christina E. Hoeve
1Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands
Hester E. de Melker
1Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands
Susan J.M. Hahné
1Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands
Gerco den Hartog
1Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands
2Radboud Center for Infectious Diseases, Radboudumc, Nijmegen, the Netherlands
Janneke H.H.M. van de Wijgert
1Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands
3Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands
Susan van den Hof
1Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands
Mirjam J. Knol
1Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands
Data Availability
All data produced in the present study are available in aggregated and anonymized form upon reasonable request to the authors.
Posted February 13, 2023.
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection in the Netherlands, September to December 2022
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, Hester E. de Melker, Susan J.M. Hahné, Gerco den Hartog, Janneke H.H.M. van de Wijgert, Susan van den Hof, Mirjam J. Knol
medRxiv 2023.02.08.23285643; doi: https://doi.org/10.1101/2023.02.08.23285643
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection in the Netherlands, September to December 2022
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, Hester E. de Melker, Susan J.M. Hahné, Gerco den Hartog, Janneke H.H.M. van de Wijgert, Susan van den Hof, Mirjam J. Knol
medRxiv 2023.02.08.23285643; doi: https://doi.org/10.1101/2023.02.08.23285643
Subject Area
Subject Areas
- Addiction Medicine (393)
- Allergy and Immunology (705)
- Anesthesia (197)
- Cardiovascular Medicine (2882)
- Dermatology (247)
- Emergency Medicine (432)
- Epidemiology (12622)
- Forensic Medicine (10)
- Gastroenterology (813)
- Genetic and Genomic Medicine (4483)
- Geriatric Medicine (409)
- Health Economics (717)
- Health Informatics (2868)
- Health Policy (1059)
- Hematology (379)
- HIV/AIDS (911)
- Medical Education (418)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4251)
- Nursing (228)
- Nutrition (622)
- Oncology (2226)
- Ophthalmology (634)
- Orthopedics (255)
- Otolaryngology (323)
- Pain Medicine (270)
- Palliative Medicine (83)
- Pathology (491)
- Pediatrics (1182)
- Primary Care Research (488)
- Public and Global Health (6829)
- Radiology and Imaging (1503)
- Respiratory Medicine (909)
- Rheumatology (431)
- Sports Medicine (376)
- Surgery (476)
- Toxicology (60)
- Transplantation (206)
- Urology (176)